What is the recommended management for chronic kidney disease, including staging, blood pressure targets, ACE inhibitor or ARB therapy, SGLT2 inhibitor use, dietary recommendations, monitoring, and referral criteria?

Management of Chronic Kidney Disease

All adults with CKD should be treated with an SGLT2 inhibitor if eGFR ≥20 ml/min per 1.73 m² and they have either albuminuria ≥200 mg/g, heart failure, or eGFR 20-45 with any level of albuminuria, combined with ACE inhibitor or ARB therapy for those with albuminuria. This represents the most significant paradigm shift in the 2024 KDIGO guidelines, establishing SGLT2 inhibitors as foundational therapy alongside RAS blockade 1.

Core Pharmacotherapy Algorithm

First-Line Therapy: RAS Inhibition

Start ACE inhibitor or ARB therapy in the following scenarios:

• CKD with diabetes + albuminuria (A2 or A3): Strong recommendation (1B) 1
• CKD without diabetes + severely increased albuminuria (A3): Strong recommendation (1B) 1
• CKD without diabetes + moderately increased albuminuria (A2): Weaker recommendation (2C) 1

Critical dosing principle: Use the highest approved tolerated dose—the proven benefits in trials were achieved at maximum doses, not submaximal therapy 1.

Monitoring after initiation or dose increase:

• Check BP, creatinine, and potassium within 2-4 weeks 1
• Continue therapy unless creatinine rises >30% within 4 weeks 1
• Do NOT stop when eGFR falls below 30 ml/min per 1.73 m²—continue even in advanced CKD 1

Managing complications:

• Hyperkalemia: Treat the hyperkalemia (dietary modification, potassium binders) rather than stopping the RASi 1
• Only reduce dose or discontinue for: symptomatic hypotension, uncontrolled hyperkalemia despite treatment, or uremic symptoms when eGFR <15 1

Second-Line Therapy: SGLT2 Inhibitors

The 2024 guidelines dramatically expanded SGLT2i indications beyond diabetes:

Strong recommendations (1A) for SGLT2i 1:

• Type 2 diabetes + CKD + eGFR ≥20 ml/min per 1.73 m²
• Any adult with CKD + eGFR ≥20 + urine ACR ≥200 mg/g
• Any adult with CKD + heart failure (regardless of albuminuria level)

Moderate recommendation (2B) 1:

• eGFR 20-45 ml/min per 1.73 m² + ACR <200 mg/g

Key management points:

• Once started, continue even if eGFR drops below 20 unless intolerance or dialysis initiation 1
• Withhold during prolonged fasting, surgery, or critical illness (ketosis risk) 1
• The initial eGFR dip is expected and reversible—do NOT stop therapy 1
• No need to increase monitoring frequency when starting SGLT2i 1

Third-Line Therapy: Nonsteroidal MRA (Finerenone)

Indication (2A recommendation) 1:

• Type 2 diabetes + eGFR >25 ml/min per 1.73 m²
• Normal potassium concentration
• Albuminuria >30 mg/g despite maximum tolerated RASi
• Best for high-risk patients with persistent albuminuria on standard therapy 1

Can be added on top of RASi + SGLT2i 1

Potassium monitoring protocol 1:

• K+ ≤4.8 mmol/L: Initiate finerenone (10 mg if eGFR 25-59; 20 mg if eGFR ≥60)
• K+ 4.9-5.5 mmol/L: Continue current dose, monitor every 4 months
• K+ >5.5 mmol/L: Hold finerenone, adjust diet/medications, recheck potassium before reinitiation

Fourth-Line Consideration: GLP-1 Receptor Agonists

Emerging evidence supports kidney-protective effects, particularly in diabetic CKD 2, 3. Consider for patients with type 2 diabetes and CKD who need additional cardiovascular and kidney protection.

Blood Pressure Management

Target BP: <130/80 mmHg for most patients at higher cardiovascular or CKD progression risk; <140/90 mmHg as general target 4, 5, 6

Combination therapy approach:

• Most patients require multiple agents 4
• After RASi, add calcium channel blocker or thiazide/thiazide-like diuretic 4, 6
• Diuretic selection based on kidney function 6

Lifestyle Modifications

Dietary sodium: <2 grams per day (equivalent to <5 grams salt) 1, 7, 5, 8

Protein intake: 0.8 g/kg/day, with potential reduction in select non-diabetic patients 7, 8

Physical activity: Moderate-intensity exercise ≥30 minutes, 5-7 days per week 4

Diet pattern: Mediterranean or vegetarian diet preferred 7

Other: Smoking cessation, weight loss if overweight 7

Monitoring Strategy

Regular assessment:

• eGFR and urine albumin-to-creatinine ratio at least annually 3
• Use KDIGO risk heatmap to stratify progression risk 3, 9
• Initial kidney ultrasound recommended for all patients 9

After medication changes:

• Creatinine, potassium, BP within 2-4 weeks of RASi initiation/dose increase 1
• Regular potassium monitoring with MRA therapy 1

Critical Pitfalls to Avoid

1. Stopping RASi when creatinine rises <30%: Small increases are expected and acceptable 1
2. Discontinuing RASi when eGFR drops below 30: Continue therapy into advanced CKD 1
3. Stopping SGLT2i for initial eGFR dip: This is reversible hemodynamic effect, not harm 1
4. Stopping RASi for hyperkalemia without trying potassium management first: Use dietary modification and binders 1
5. Using submaximal RASi doses: Titrate to maximum tolerated dose for proven benefit 1
6. Failing to measure albuminuria: Required for risk stratification and SGLT2i indication 3, 9

Nephrotoxin Stewardship

Educate patients on sick-day medication management—withholding certain medications during acute illness to prevent acute kidney injury 2. This includes temporary discontinuation of RASi, diuretics, NSAIDs, and metformin during volume depletion or acute illness.